Reducing disease burden in an influenza pandemic by targeted delivery of neuraminidase inhibitors: mathematical models in the Australian context.
Identifieur interne : 000492 ( PubMed/Curation ); précédent : 000491; suivant : 000493Reducing disease burden in an influenza pandemic by targeted delivery of neuraminidase inhibitors: mathematical models in the Australian context.
Auteurs : Robert Moss [Australie] ; James M. Mccaw [Australie] ; Allen C. Cheng [Australie] ; Aeron C. Hurt [Australie] ; Jodie Mcvernon [Australie]Source :
- BMC infectious diseases [ 1471-2334 ] ; 2016.
Descripteurs français
- KwdFr :
- Antienzymes (administration et posologie), Antienzymes (usage thérapeutique), Antiviraux (administration et posologie), Antiviraux (usage thérapeutique), Australie (épidémiologie), Coût de la maladie, Grippe humaine (), Grippe humaine (traitement médicamenteux), Grippe humaine (transmission), Grippe humaine (épidémiologie), Humains, Modèles théoriques, Pandémies (), Sialidase (antagonistes et inhibiteurs), Évaluation des risques.
- MESH :
- administration et posologie : Antienzymes, Antiviraux.
- antagonistes et inhibiteurs : Sialidase.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Antienzymes, Antiviraux, Grippe humaine.
- épidémiologie : Australie, Grippe humaine.
- Coût de la maladie, Grippe humaine, Humains, Modèles théoriques, Pandémies, Évaluation des risques.
English descriptors
- KwdEn :
- Antiviral Agents (administration & dosage), Antiviral Agents (therapeutic use), Australia (epidemiology), Cost of Illness, Enzyme Inhibitors (administration & dosage), Enzyme Inhibitors (therapeutic use), Humans, Influenza, Human (drug therapy), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Influenza, Human (transmission), Models, Theoretical, Neuraminidase (antagonists & inhibitors), Pandemics (prevention & control), Risk Assessment.
- MESH :
- chemical , administration & dosage : Antiviral Agents, Enzyme Inhibitors.
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , therapeutic use : Antiviral Agents, Enzyme Inhibitors.
- drug therapy : Influenza, Human.
- epidemiology : Australia, Influenza, Human.
- prevention & control : Influenza, Human, Pandemics.
- transmission : Influenza, Human.
- Cost of Illness, Humans, Models, Theoretical, Risk Assessment.
Abstract
Many nations maintain stockpiles of neuraminidase inhibitor (NAI) antiviral agents for use in influenza pandemics to reduce transmission and mitigate the course of clinical infection. Pandemic preparedness plans include the use of these stockpiles to deliver proportionate responses, informed by emerging evidence of clinical impact. Recent uncertainty about the effectiveness of NAIs has prompted these nations to reconsider the role of NAIs in pandemic response, with implications for pandemic planning and for NAI stockpile size.
DOI: 10.1186/s12879-016-1866-7
PubMed: 27724915
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000492
Links to Exploration step
pubmed:27724915Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reducing disease burden in an influenza pandemic by targeted delivery of neuraminidase inhibitors: mathematical models in the Australian context.</title><author><name sortKey="Moss, Robert" sort="Moss, Robert" uniqKey="Moss R" first="Robert" last="Moss">Robert Moss</name><affiliation wicri:level="1"><nlm:affiliation>Modelling and Simulation Unit Centre for Epidemiology and Biostatistics Melbourne School of Population and Global Health, The University of Melbourne, Level 3, 207 Bouverie St, Melbourne, 3010, Victoria, Australia. rgmoss@unimelb.edu.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Modelling and Simulation Unit Centre for Epidemiology and Biostatistics Melbourne School of Population and Global Health, The University of Melbourne, Level 3, 207 Bouverie St, Melbourne, 3010, Victoria</wicri:regionArea></affiliation></author><author><name sortKey="Mccaw, James M" sort="Mccaw, James M" uniqKey="Mccaw J" first="James M" last="Mccaw">James M. Mccaw</name><affiliation wicri:level="1"><nlm:affiliation>Modelling and Simulation Unit Centre for Epidemiology and Biostatistics Melbourne School of Population and Global Health, The University of Melbourne, Level 3, 207 Bouverie St, Melbourne, 3010, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Modelling and Simulation Unit Centre for Epidemiology and Biostatistics Melbourne School of Population and Global Health, The University of Melbourne, Level 3, 207 Bouverie St, Melbourne, 3010, Victoria</wicri:regionArea></affiliation></author><author><name sortKey="Cheng, Allen C" sort="Cheng, Allen C" uniqKey="Cheng A" first="Allen C" last="Cheng">Allen C. Cheng</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Disease Epidemiology Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Infectious Disease Epidemiology Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne</wicri:regionArea></affiliation></author><author><name sortKey="Hurt, Aeron C" sort="Hurt, Aeron C" uniqKey="Hurt A" first="Aeron C" last="Hurt">Aeron C. Hurt</name><affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute, Melbourne</wicri:regionArea></affiliation></author><author><name sortKey="Mcvernon, Jodie" sort="Mcvernon, Jodie" uniqKey="Mcvernon J" first="Jodie" last="Mcvernon">Jodie Mcvernon</name><affiliation wicri:level="1"><nlm:affiliation>Modelling and Simulation Unit Centre for Epidemiology and Biostatistics Melbourne School of Population and Global Health, The University of Melbourne, Level 3, 207 Bouverie St, Melbourne, 3010, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Modelling and Simulation Unit Centre for Epidemiology and Biostatistics Melbourne School of Population and Global Health, The University of Melbourne, Level 3, 207 Bouverie St, Melbourne, 3010, Victoria</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27724915</idno><idno type="pmid">27724915</idno><idno type="doi">10.1186/s12879-016-1866-7</idno><idno type="wicri:Area/PubMed/Corpus">000492</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000492</idno><idno type="wicri:Area/PubMed/Curation">000492</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000492</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Reducing disease burden in an influenza pandemic by targeted delivery of neuraminidase inhibitors: mathematical models in the Australian context.</title><author><name sortKey="Moss, Robert" sort="Moss, Robert" uniqKey="Moss R" first="Robert" last="Moss">Robert Moss</name><affiliation wicri:level="1"><nlm:affiliation>Modelling and Simulation Unit Centre for Epidemiology and Biostatistics Melbourne School of Population and Global Health, The University of Melbourne, Level 3, 207 Bouverie St, Melbourne, 3010, Victoria, Australia. rgmoss@unimelb.edu.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Modelling and Simulation Unit Centre for Epidemiology and Biostatistics Melbourne School of Population and Global Health, The University of Melbourne, Level 3, 207 Bouverie St, Melbourne, 3010, Victoria</wicri:regionArea></affiliation></author><author><name sortKey="Mccaw, James M" sort="Mccaw, James M" uniqKey="Mccaw J" first="James M" last="Mccaw">James M. Mccaw</name><affiliation wicri:level="1"><nlm:affiliation>Modelling and Simulation Unit Centre for Epidemiology and Biostatistics Melbourne School of Population and Global Health, The University of Melbourne, Level 3, 207 Bouverie St, Melbourne, 3010, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Modelling and Simulation Unit Centre for Epidemiology and Biostatistics Melbourne School of Population and Global Health, The University of Melbourne, Level 3, 207 Bouverie St, Melbourne, 3010, Victoria</wicri:regionArea></affiliation></author><author><name sortKey="Cheng, Allen C" sort="Cheng, Allen C" uniqKey="Cheng A" first="Allen C" last="Cheng">Allen C. Cheng</name><affiliation wicri:level="1"><nlm:affiliation>Infectious Disease Epidemiology Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Infectious Disease Epidemiology Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne</wicri:regionArea></affiliation></author><author><name sortKey="Hurt, Aeron C" sort="Hurt, Aeron C" uniqKey="Hurt A" first="Aeron C" last="Hurt">Aeron C. Hurt</name><affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute, Melbourne</wicri:regionArea></affiliation></author><author><name sortKey="Mcvernon, Jodie" sort="Mcvernon, Jodie" uniqKey="Mcvernon J" first="Jodie" last="Mcvernon">Jodie Mcvernon</name><affiliation wicri:level="1"><nlm:affiliation>Modelling and Simulation Unit Centre for Epidemiology and Biostatistics Melbourne School of Population and Global Health, The University of Melbourne, Level 3, 207 Bouverie St, Melbourne, 3010, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Modelling and Simulation Unit Centre for Epidemiology and Biostatistics Melbourne School of Population and Global Health, The University of Melbourne, Level 3, 207 Bouverie St, Melbourne, 3010, Victoria</wicri:regionArea></affiliation></author></analytic><series><title level="j">BMC infectious diseases</title><idno type="eISSN">1471-2334</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (therapeutic use)</term><term>Australia (epidemiology)</term><term>Cost of Illness</term><term>Enzyme Inhibitors (administration & dosage)</term><term>Enzyme Inhibitors (therapeutic use)</term><term>Humans</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Influenza, Human (transmission)</term><term>Models, Theoretical</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Pandemics (prevention & control)</term><term>Risk Assessment</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antienzymes (administration et posologie)</term><term>Antienzymes (usage thérapeutique)</term><term>Antiviraux (administration et posologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Australie (épidémiologie)</term><term>Coût de la maladie</term><term>Grippe humaine ()</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (transmission)</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Modèles théoriques</term><term>Pandémies ()</term><term>Sialidase (antagonistes et inhibiteurs)</term><term>Évaluation des risques</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Enzyme Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Enzyme Inhibitors</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antienzymes</term><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Australia</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term><term>Pandemics</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antienzymes</term><term>Antiviraux</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Australie</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cost of Illness</term><term>Humans</term><term>Models, Theoretical</term><term>Risk Assessment</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Coût de la maladie</term><term>Grippe humaine</term><term>Humains</term><term>Modèles théoriques</term><term>Pandémies</term><term>Évaluation des risques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Many nations maintain stockpiles of neuraminidase inhibitor (NAI) antiviral agents for use in influenza pandemics to reduce transmission and mitigate the course of clinical infection. Pandemic preparedness plans include the use of these stockpiles to deliver proportionate responses, informed by emerging evidence of clinical impact. Recent uncertainty about the effectiveness of NAIs has prompted these nations to reconsider the role of NAIs in pandemic response, with implications for pandemic planning and for NAI stockpile size.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">27724915</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Reducing disease burden in an influenza pandemic by targeted delivery of neuraminidase inhibitors: mathematical models in the Australian context.</ArticleTitle><Pagination><MedlinePgn>552</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Many nations maintain stockpiles of neuraminidase inhibitor (NAI) antiviral agents for use in influenza pandemics to reduce transmission and mitigate the course of clinical infection. Pandemic preparedness plans include the use of these stockpiles to deliver proportionate responses, informed by emerging evidence of clinical impact. Recent uncertainty about the effectiveness of NAIs has prompted these nations to reconsider the role of NAIs in pandemic response, with implications for pandemic planning and for NAI stockpile size.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We combined a dynamic model of influenza epidemiology with a model of the clinical care pathways in the Australian health care system to identify effective NAI strategies for reducing morbidity and mortality in pandemic events, and the stockpile requirements for these strategies. The models were informed by a 2015 assessment of NAI effectiveness against susceptibility, pathogenicity, and transmission of influenza.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Liberal distribution of NAIs for early treatment in outpatient settings yielded the greatest benefits in all of the considered scenarios. Restriction of community-based treatment to risk groups was effective in those groups, but failed to prevent the large proportion of cases arising from lower risk individuals who comprise the majority of the population.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These targeted strategies are only effective if they can be deployed within the constraints of existing health care infrastructure. This finding highlights the critical importance of identifying optimal models of care delivery for effective emergency health care response.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moss</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-4568-2012</Identifier><AffiliationInfo><Affiliation>Modelling and Simulation Unit Centre for Epidemiology and Biostatistics Melbourne School of Population and Global Health, The University of Melbourne, Level 3, 207 Bouverie St, Melbourne, 3010, Victoria, Australia. rgmoss@unimelb.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCaw</LastName><ForeName>James M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Modelling and Simulation Unit Centre for Epidemiology and Biostatistics Melbourne School of Population and Global Health, The University of Melbourne, Level 3, 207 Bouverie St, Melbourne, 3010, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Mathematics and Statistics, The University of Melbourne, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Murdoch Childrens Research Institute, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Allen C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Infectious Disease Epidemiology Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infection Prevention and Healthcare Epidemiology Unit, Alfred Health, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurt</LastName><ForeName>Aeron C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McVernon</LastName><ForeName>Jodie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Modelling and Simulation Unit Centre for Epidemiology and Biostatistics Melbourne School of Population and Global Health, The University of Melbourne, Level 3, 207 Bouverie St, Melbourne, 3010, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Murdoch Childrens Research Institute, Melbourne, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N">Australia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="Y">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008962" MajorTopicYN="N">Models, Theoretical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Emergency response</Keyword><Keyword MajorTopicYN="Y">Influenza</Keyword><Keyword MajorTopicYN="Y">Neuraminidase inhibitor</Keyword><Keyword MajorTopicYN="Y">Pandemic preparedness</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>04</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>09</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27724915</ArticleId><ArticleId IdType="doi">10.1186/s12879-016-1866-7</ArticleId><ArticleId IdType="pii">10.1186/s12879-016-1866-7</ArticleId><ArticleId IdType="pmc">PMC5057455</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>N Engl J Med. 2009 Jun 18;360(25):2595-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19423872</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2012 Apr 05;17(14):null</Citation><ArticleIdList><ArticleId IdType="pubmed">22516004</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2014 Mar;8(2):194-200</Citation><ArticleIdList><ArticleId IdType="pubmed">24382379</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2009 Aug;9(8):473-81</Citation><ArticleIdList><ArticleId IdType="pubmed">19628172</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiol Infect. 2010 Nov;138(11):1531-41</Citation><ArticleIdList><ArticleId IdType="pubmed">20594381</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2012 Apr 18;(4):CD002744</Citation><ArticleIdList><ArticleId IdType="pubmed">22513907</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011 Feb 04;6(2):e14505</Citation><ArticleIdList><ArticleId IdType="pubmed">21346794</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Biol Sci. 2008 Mar 7;275(1634):501-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18156123</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2016 May;10 (3):192-204</Citation><ArticleIdList><ArticleId IdType="pubmed">26602067</ArticleId></ArticleIdList></Reference><Reference><Citation>J Public Health (Oxf). 2014 Mar;36(1):5-12</Citation><ArticleIdList><ArticleId IdType="pubmed">23735960</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemics. 2014 Sep;8:18-27</Citation><ArticleIdList><ArticleId IdType="pubmed">25240900</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2010 Jul;65(7):1330-46</Citation><ArticleIdList><ArticleId IdType="pubmed">20488984</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2012 Jul;6(4):299-303</Citation><ArticleIdList><ArticleId IdType="pubmed">22118572</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2014 May;69(5):1397-406</Citation><ArticleIdList><ArticleId IdType="pubmed">24346762</ArticleId></ArticleIdList></Reference><Reference><Citation>Fam Pract. 2013 Apr;30(2):125-33</Citation><ArticleIdList><ArticleId IdType="pubmed">22997224</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2011 Sep 30;11:257</Citation><ArticleIdList><ArticleId IdType="pubmed">21958428</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2015 May 2;385(9979):1729-37</Citation><ArticleIdList><ArticleId IdType="pubmed">25640810</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Public Health. 2010 Apr;34(2):113-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23331352</ArticleId></ArticleIdList></Reference><Reference><Citation>J R Soc Interface. 2008 Jun 6;5(23):631-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17916550</ArticleId></ArticleIdList></Reference><Reference><Citation>Math Biosci. 2007 Oct;209(2):336-60</Citation><ArticleIdList><ArticleId IdType="pubmed">17416393</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2014 Apr 10;(4):CD008965</Citation><ArticleIdList><ArticleId IdType="pubmed">24718923</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemics. 2012 Dec;4(4):219-26</Citation><ArticleIdList><ArticleId IdType="pubmed">23351374</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2011 Jul;8(7):e1001053</Citation><ArticleIdList><ArticleId IdType="pubmed">21750667</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2010 Oct 07;15(40):null</Citation><ArticleIdList><ArticleId IdType="pubmed">20946757</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Technol Assess. 2010 Dec;14 (55):115-92</Citation><ArticleIdList><ArticleId IdType="pubmed">21208549</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2010 Oct 05;7(10):null</Citation><ArticleIdList><ArticleId IdType="pubmed">20957189</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Public Health. 2011 May 20;11:353</Citation><ArticleIdList><ArticleId IdType="pubmed">21599920</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2014 May;2(5):395-404</Citation><ArticleIdList><ArticleId IdType="pubmed">24815805</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2010 May 25;10:128</Citation><ArticleIdList><ArticleId IdType="pubmed">20497585</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000492 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000492 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:27724915
|texte= Reducing disease burden in an influenza pandemic by targeted delivery of neuraminidase inhibitors: mathematical models in the Australian context.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:27724915" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |